1. Pfizer. NCT05047601. A study of a potential oral treatment to prevent COVID-19 in adults who are exposed to household member(s) with a confirmed symptomatic COVID-19 infection. 2022. https://www.clinicaltrials.gov/. Accessed 21 Feb 2022.
2. Pfizer. NCT05011513. Evaluation of protease inhibition for COVID-19 in standard-risk patients (EPIC-SR). 2022. https://www.clinicaltrials.gov/. Accessed 21 Feb 2022.
3. Pfizer. NCT04960202. EPIC-HR: study of oral PF-07321332/ritonavir compared with placebo in nonhospitalized high risk adults with COVID-19. 2022. https://www.clinicaltrials.gov/. Accessed 21 Feb 2022.
4. Fenton C, Lamb YN. COVID-19: state of the vaccination. Drugs Ther Perspect. 2021;37:508–18.
5. Lamb YN. BNT162b2 mRNA COVID-19 vaccine: first approval. Drugs. 2021;81:495–501.